MaxCyte, Inc. (NASDAQ:MXCT) Shares Purchased by Mudita Advisors LLP

Mudita Advisors LLP grew its position in MaxCyte, Inc. (NASDAQ:MXCT - Free Report) by 5.6% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,153,441 shares of the company's stock after purchasing an additional 167,101 shares during the quarter. MaxCyte makes up approximately 6.7% of Mudita Advisors LLP's portfolio, making the stock its 6th largest holding. Mudita Advisors LLP owned 2.99% of MaxCyte worth $12,267,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Swedbank AB acquired a new stake in shares of MaxCyte in the first quarter valued at about $6,704,000. Vanguard Group Inc. boosted its position in shares of MaxCyte by 1.2% in the first quarter. Vanguard Group Inc. now owns 5,347,112 shares of the company's stock valued at $22,404,000 after acquiring an additional 65,004 shares during the period. Lazard Asset Management LLC grew its stake in shares of MaxCyte by 27.4% in the first quarter. Lazard Asset Management LLC now owns 467,687 shares of the company's stock worth $1,958,000 after acquiring an additional 100,555 shares during the last quarter. American Century Companies Inc. increased its position in MaxCyte by 10.7% during the second quarter. American Century Companies Inc. now owns 144,110 shares of the company's stock worth $565,000 after acquiring an additional 13,904 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its stake in MaxCyte by 20.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 25,199 shares of the company's stock valued at $106,000 after purchasing an additional 4,320 shares during the last quarter. 68.81% of the stock is currently owned by institutional investors and hedge funds.

MaxCyte Stock Up 4.4 %

NASDAQ MXCT traded up $0.15 during midday trading on Wednesday, hitting $3.53. The company had a trading volume of 610,534 shares, compared to its average volume of 534,128. The firm has a fifty day simple moving average of $3.71 and a two-hundred day simple moving average of $4.13. MaxCyte, Inc. has a fifty-two week low of $3.16 and a fifty-two week high of $5.55. The stock has a market cap of $372.34 million, a price-to-earnings ratio of -9.94 and a beta of 1.40.

MaxCyte (NASDAQ:MXCT - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.02. The firm had revenue of $8.16 million for the quarter, compared to analyst estimates of $7.50 million. MaxCyte had a negative return on equity of 16.00% and a negative net margin of 78.36%. During the same period in the previous year, the company posted ($0.11) earnings per share. As a group, equities analysts predict that MaxCyte, Inc. will post -0.43 earnings per share for the current year.

Insider Transactions at MaxCyte

In related news, Director Stanley C. Erck sold 29,767 shares of the business's stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $3.97, for a total value of $118,174.99. Following the completion of the transaction, the director now owns 269,118 shares in the company, valued at $1,068,398.46. The trade was a 9.96 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Over the last 90 days, insiders sold 57,374 shares of company stock valued at $220,957. Corporate insiders own 3.00% of the company's stock.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.